Filing Details

Accession Number:
0001567619-22-017725
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-09-22 16:13:58
Reporting Period:
2022-09-20
Accepted Time:
2022-09-22 16:13:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1668397 Medpace Holdings Inc. MEDP () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1622058 J. August Troendle C/O Medpace Holdings, Inc.
5375 Medpace Way
Cincinnati OH 45227
Ceo Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-09-20 94,119 $155.14 6,331,474 No 4 P Indirect By Medpace Investors, LLC
Common Stock Acquisiton 2022-09-21 94,119 $161.63 6,425,593 No 4 P Indirect By Medpace Investors, LLC
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Medpace Investors, LLC
No 4 P Indirect By Medpace Investors, LLC
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 806,643 Direct
Footnotes
  1. The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.
  2. The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $151.72 to $157.02. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
  3. The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
  4. The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $157.83 to $163.71. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.